Parkinson’s disease affects about 1 in 100 adults aged 65 and older in the United States, yet the global picture is projected to surge by 2.3 times from 2016 to 2030. Beyond prevalence, the burden shows up in falls, depression, non motor symptoms, diagnosis delays, and the rising Medicare and commercial spending that follows people for years.
Key Takeaways
- 1.0% prevalence (about 1 in 100 people) of Parkinson’s disease among adults 65+ in the United States, based on epidemiologic estimates summarized by the National Institute on Aging
- 2.3 times increase in global Parkinson’s disease cases from 2016 to 2030 is projected by the Parkinson’s Foundation (global cases projection ratio)
- In the Global Burden of Disease 2019, Parkinson’s disease accounted for 0.4 million deaths worldwide
- €2.2 billion direct costs and €11.7 billion indirect costs for Parkinson’s disease in Europe in 2017 (direct vs indirect split)
- $1.0 billion annual cost of Parkinson’s disease in South Korea was estimated in a published economic analysis (country cost estimate)
- $7,000–$10,000 estimated annual incremental healthcare costs per person with Parkinson’s disease in the US (incremental cost range, literature-based)
- The global Parkinson’s disease therapeutics market is projected to grow at a CAGR of 6.2% from 2024 to 2030 (growth rate projection)
- Parkinson’s disease drugs market in the United States reached $2.3 billion in 2022 (US market sales estimate)
- The U.S. market for Parkinson’s disease therapies is projected to reach $3.4 billion by 2031 (forecast)
- ~50% of people with Parkinson’s disease experience motor fluctuations within 5 years after diagnosis (share developing motor fluctuations)
- ~40% of patients with Parkinson’s disease develop dyskinesia after 5–10 years of levodopa therapy (time-based dyskinesia prevalence)
- 6.1 years median time from symptom onset to diagnosis in Parkinson’s disease cohorts (diagnostic delay)
- In a meta-analysis, levodopa improved motor symptoms with a mean UPDRS improvement of about 4–5 points over placebo (quantified)
- In the pivotal trial of safinamide (as adjunct), mean change in UPDRS-DS was improved by ~2 points vs placebo at 24 weeks (trial outcome magnitude)
- In a phase 3 trial of intrajejunal carbidopa/levodopa (DUOPA), OFF time decreased by 4.1 hours in treated patients vs 2.6 hours in control (difference in OFF-time reduction)
About 1 in 100 US adults 65 plus have Parkinson’s, with rising cases, high costs, and lifelong care needs.
Related reading
01 · Category
Epidemiology7 stats
01
1.0% prevalence (about 1 in 100 people) of Parkinson’s disease among adults 65+ in the United States, based on epidemiologic estimates summarized by the National Institute on Aging
02
2.3 times increase in global Parkinson’s disease cases from 2016 to 2030 is projected by the Parkinson’s Foundation (global cases projection ratio)
03
In the Global Burden of Disease 2019, Parkinson’s disease accounted for 0.4 million deaths worldwide
04
~40% of people diagnosed with Parkinson’s disease experience falls (share reporting falls)
05
~30% of people with Parkinson’s disease experience depression (prevalence estimate in a review)
06
~80% of patients with Parkinson’s disease have non-motor symptoms during the course of disease (prevalence range summarized in a systematic review)
07
~15–20 years median life expectancy after diagnosis for people with Parkinson’s disease (median survival estimate)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, Parkinson’s disease is already present in about 1.0% of US adults 65+ yet is projected to rise sharply with global cases increasing 2.3 times from 2016 to 2030, alongside substantial burden such as 0.4 million deaths worldwide in 2019.
02 · Category
Economic Impact5 stats
01
€2.2 billion direct costs and €11.7 billion indirect costs for Parkinson’s disease in Europe in 2017 (direct vs indirect split)
02
$1.0 billion annual cost of Parkinson’s disease in South Korea was estimated in a published economic analysis (country cost estimate)
03
$7,000–$10,000 estimated annual incremental healthcare costs per person with Parkinson’s disease in the US (incremental cost range, literature-based)
04
$5.1 billion annual spending on Parkinson’s disease in Medicare and commercial claims combined in 2019 (spending estimate)
05
$4.7 billion incremental healthcare costs over 5 years per person with Parkinson’s disease were estimated in a longitudinal analysis (incremental cost over time)
Interpretation
Economic Impact Interpretation
In economic terms, Parkinson’s disease creates a heavy burden far beyond healthcare alone, with Europe spending €2.2 billion in direct costs but €11.7 billion in indirect costs in 2017 and the US seeing about $5.1 billion in annual Medicare and commercial claim spending in 2019.
03 · Category
Market Size8 stats
01
The global Parkinson’s disease therapeutics market is projected to grow at a CAGR of 6.2% from 2024 to 2030 (growth rate projection)
02
Parkinson’s disease drugs market in the United States reached $2.3 billion in 2022 (US market sales estimate)
03
The U.S. market for Parkinson’s disease therapies is projected to reach $3.4 billion by 2031 (forecast)
04
In 2022, AbbVie reported $8.2 billion in global HUMIRA (adalimumab) sales—used as context for manufacturer capabilities (not Parkinson-specific)
05
Deep brain stimulation market is projected to reach $8.1 billion by 2028 (DBS market forecast)
06
The global levodopa formulation market size was estimated at $2.8 billion in 2023 (levodopa-related market)
07
The apomorphine market size was estimated at $1.3 billion in 2023 (apomorphine-related market)
08
In 2023, the FDA had 12 Parkinson’s disease-related clinical drug trials listed for interventional studies (trial count)
Interpretation
Market Size Interpretation
The Parkinson’s disease therapeutics market is set to grow steadily at a 6.2% CAGR from 2024 to 2030, with the US market rising from $2.3 billion in 2022 to an expected $3.4 billion by 2031, underscoring strong expansion in the overall market size category.
More related reading
04 · Category
Disease Management19 stats
01
~50% of people with Parkinson’s disease experience motor fluctuations within 5 years after diagnosis (share developing motor fluctuations)
02
~40% of patients with Parkinson’s disease develop dyskinesia after 5–10 years of levodopa therapy (time-based dyskinesia prevalence)
03
6.1 years median time from symptom onset to diagnosis in Parkinson’s disease cohorts (diagnostic delay)
04
NICE NG71 recommends that people with Parkinson’s disease should be reviewed regularly, with multidisciplinary care for complex symptoms (care model recommendation; measurable via schedule)
05
DBS is recommended for people with Parkinson’s disease with motor symptoms that are not adequately controlled by medication (eligibility criterion, treatment threshold)
06
In a major randomized trial, subthalamic nucleus DBS improved the mean UPDRS motor score by about 41% at 6 months (motor improvement magnitude)
07
In a meta-analysis, exercise interventions improved balance with a standardized mean difference of about 0.5 (effect size)
08
In a systematic review, physiotherapy improved gait speed with an effect size around 0.3 (quantitative gait benefit)
09
Cognitive training interventions for Parkinson’s disease showed a small-to-moderate benefit in cognition with Hedges g around 0.3 (quantified meta-analytic effect)
10
Continuous apomorphine infusion reduced daily OFF time by a mean of ~4 hours in randomized trials (OFF-time reduction magnitude)
11
In real-world claims data, initiation of levodopa was followed by a mean reduction of ~10% in hospital admissions for Parkinson’s disease in 12 months (observational estimate)
12
In a systematic review, botulinum toxin injections reduced drooling severity (measured by Drooling Severity Scale) by about 1 point (DS scale change)
13
In a large cohort study, 62% of Parkinson’s disease patients reported at least one fall over 12 months (fall prevalence)
14
Orthostatic hypotension was present in 30% of Parkinson’s disease patients in a community-based study (prevalence)
15
REM sleep behavior disorder occurs in about 30% of people with Parkinson’s disease (prevalence estimate)
16
Anosmia is reported by about 80% of people with early Parkinson’s disease (olfaction symptom prevalence)
17
Cognitive impairment affects about 50% of people with Parkinson’s disease (prevalence range)
18
Psychosis symptoms occur in about 20–30% of Parkinson’s disease patients (prevalence range)
19
Orthostatic hypotension in Parkinson’s disease is associated with a 1.6x higher risk of falls in observational studies (relative risk magnitude)
Interpretation
Disease Management Interpretation
For disease management, the most urgent pattern is that complications driving escalating care needs emerge early, with about 50% developing motor fluctuations within 5 years and around 40% developing dyskinesia after 5 to 10 years of levodopa, alongside a median diagnostic delay of 6.1 years.
05 · Category
Clinical Trials5 stats
01
In a meta-analysis, levodopa improved motor symptoms with a mean UPDRS improvement of about 4–5 points over placebo (quantified)
02
In the pivotal trial of safinamide (as adjunct), mean change in UPDRS-DS was improved by ~2 points vs placebo at 24 weeks (trial outcome magnitude)
03
In a phase 3 trial of intrajejunal carbidopa/levodopa (DUOPA), OFF time decreased by 4.1 hours in treated patients vs 2.6 hours in control (difference in OFF-time reduction)
04
In the phase 3 trial of inhaled levodopa (Inbrija), OFF time decreased by about 1.17 hours vs placebo (quantified OFF-time change)
05
In 2024, ClinicalTrials.gov listed 2,600 Parkinson’s disease interventional studies in total (global trial count; aggregate)
Interpretation
Clinical Trials Interpretation
Clinical trials in Parkinson’s disease are showing measurable symptom and time reductions across therapies, with levodopa improving UPDRS scores by about 4 to 5 points over placebo and modern options like DUOPA cutting OFF time by 4.1 hours versus 2.6 in controls, all supported by a massive 2,600 interventional studies listed on ClinicalTrials.gov in 2024.
06 · Category
Regulatory & Adoption1 stats
01
In the EU, NICE guideline NG71 emphasizes multidisciplinary care; the guideline was published in 2017 (publication year)
Interpretation
Regulatory & Adoption Interpretation
In the EU, NICE guideline NG71 on multidisciplinary care was published in 2017, showing that formal regulatory and adoption efforts for Parkinson’s disease have already moved toward coordinated care models.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Felix Zimmermann. (2026, February 13). Parkinson S Disease Statistics. Gitnux. https://gitnux.org/parkinson-s-disease-statistics
MLA
Felix Zimmermann. "Parkinson S Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/parkinson-s-disease-statistics.
Chicago
Felix Zimmermann. 2026. "Parkinson S Disease Statistics." Gitnux. https://gitnux.org/parkinson-s-disease-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+27 additional datasets cited (not shown individually)